FIELD: pharmacology.SUBSTANCE: invention relates to a compound of formula Ior a pharmaceutically acceptable salt or optical isomer thereof, wherein, in formula I, n is selected from 1 to 7, R1 means C3-C7 hydrocarbyl, which may be unsubstituted or optionally substituted by halogen, alkoxy, alkoxycarbonyl, heterocyclyl or aryl； R2 is aryl or heteroaryl containing one or more heteroatoms selected from N, O or S which may be unsubstituted or optionally substituted by one or more substituents of halogen, phenyl, -OR6, -SR6, -NR6R7, -NHCOR6, -CONR6R7, -CN, -NO2, -COOR6, -CF3 or linear or branched C1-C4 hydrocarbyl, R6 and R7 can denote a hydrogen atom or linear or branched C1-C4 hydrocarbyl； R3 is hydroxyl, halogen, alkoxy or acyloxy. Alkoxy or acyloxy may be unsubstituted or optionally substituted by halogen, hydroxyl, alkoxy, hydrocarbyl, alkoxyhydrocarbyl, heterocyclyl or aryl； R4 and R5 may or may not be present, and, independently, can mean, without limitation, a substituent such as halogen, hydroxyl, alkoxy, hydrocarbyl, alkoxyhydrocarbyl, heterocyclyl or aryl when these radicals are present. Y is linear or branched C1-C7 alkyl or - (CH2-O-CH2)m-, which may be optionally substituted by halogen, hydroxyl, alkoxy, alkoxyalkyl, unsaturated hydrocarbyl, cyclic hydrocarbyl or heterocyclyl. M is 1-3； X- means an acid residue or hydroxyl, the said compounds having a selective antagonistic effect on the M1 and M3 receptors subtypes, but insignificantly affect the M2 receptor subtype.EFFECT: compound application efficiency increase.24 cl, 5 tbl, 33 exИзобретение относится к соединению формулы I:или его фармацевтически приемлемые соль или оптический изомер, где в формуле I: n выбран из 1-7, R1 обозначает С3-С7 гидрокарбил, который может быть незамещенным или необязательно замещенным галогеном, алкокси, алкоксикарбонилом, гетероциклилом или арилом； R2 обозначает арил или гетероарил, содержащий один или более гетероатомов, выбранных из N, О или S, который может быть незамещенн
